Loading...
XCSE
EMBLA
Market cap1.83bUSD
May 03, Last price  
29.50DKK
Name

Ossur hf

Chart & Performance

D1W1MN
No data to show
P/E
26.80
P/S
2.14
EPS
0.16
Div Yield, %
Shrs. gr., 5y
0.10%
Rev. gr., 5y
4.49%
Revenues
855m
+8.81%
436,274,000509,357,000483,034,000519,567,768567,818,410612,876,000686,264,000629,503,000718,669,000718,650,000785,683,000854,889,000
Net income
68m
+16.94%
40,483,00059,447,00051,243,00050,913,34757,563,63679,754,00066,040,0006,214,00063,994,00042,513,00058,389,00068,278,000
CFO
116m
+23.05%
66,154,00085,133,00065,500,00066,161,70973,779,71574,287,00095,413,00092,241,000100,530,00060,771,00094,324,000116,066,000
Dividend
Mar 13, 20200.15 DKK/sh

Profile

Össur hf., together with its subsidiaries, designs, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers prosthetics products, including artificial limbs and related products for amputees; and lower and upper limb prosthetic components, including feet, knees, hands, fingers, liners, and other components. The company also provides bracing and supports products, such as supporting devices for spinal, knee, hip, foot, ankle, and hands that are primarily used to support joints and other body parts for therapeutic and preventative purposes; and injury solutions to enhance the healing process of bone and soft tissue injuries. It serves specialized healthcare providers, including orthopedic and prosthetic clinics, hospitals, and surgery centers. The company sells its products through its direct sales networks and distributors. Össur hf. was founded in 1971 and is headquartered in Reykjavik, Iceland. Össur hf. is a subsidiary of William Demant Invest A/S.
IPO date
Jan 01, 2009
Employees
4,000
Domiciled in
IS
Incorporated in
IS

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
854,889
8.81%
785,683
9.33%
718,650
0.00%
Cost of revenue
742,136
698,223
678,670
Unusual Expense (Income)
NOPBT
112,753
87,460
39,980
NOPBT Margin
13.19%
11.13%
5.56%
Operating Taxes
21,603
17,206
12,962
Tax Rate
19.16%
19.67%
32.42%
NOPAT
91,150
70,254
27,018
Net income
68,278
16.94%
58,389
37.34%
42,513
-33.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
(9,941)
BB yield
Debt
Debt current
52,756
43,325
86,837
Long-term debt
589,448
558,805
394,085
Deferred revenue
8,589
7,277
6,042
Other long-term liabilities
55,882
24,017
139,497
Net debt
556,041
504,415
386,821
Cash flow
Cash from operating activities
116,066
94,324
60,771
CAPEX
(39,227)
(42,278)
(25,942)
Cash from investing activities
(104,770)
(57,147)
(66,261)
Cash from financing activities
5,761
(40,959)
3,789
FCF
62,624
22,973
21,597
Balance
Cash
86,163
72,653
76,631
Long term investments
25,062
17,470
Excess cash
43,419
58,431
58,168
Stockholders' equity
767,454
643,528
574,080
Invested Capital
1,301,540
1,145,601
1,076,414
ROIC
7.45%
6.32%
2.57%
ROCE
8.16%
7.09%
3.42%
EV
Common stock shares outstanding
426,659
420,318
417,831
Price
Market cap
EV
EBITDA
168,726
137,380
89,345
EV/EBITDA
Interest
23,248
20,720
12,947
Interest/NOPBT
20.62%
23.69%
32.38%